S Bank Fund Management Ltd Acquires New Holdings in Hologic, Inc. $HOLX

Key Points

• S Bank Fund Management Ltd purchased 4,301 shares of Hologic, Inc., amounting to approximately $266,000, during the first quarter of the year.
• Hologic reported $1.08 earnings per share for its most recent quarter, beating expectations and showing a 1.2% increase in revenue year-over-year.
• Institutional investors currently own 94.73% of Hologic's stock, indicating strong interest from large financial entities.

S Bank Fund Management Ltd purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 4,301 shares of the medical equipment provider's stock, valued at approximately $266,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Federated Hermes Inc. increased its position in shares of Hologic by 35.8% during the fourth quarter. Federated Hermes Inc. now owns 7,720 shares of the medical equipment provider's stock worth $557,000 after buying an additional 2,036 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Hologic during the fourth quarter worth $27,007,000. Sterling Capital Management LLC increased its position in shares of Hologic by 51.3% during the fourth quarter. Sterling Capital Management LLC now owns 14,099 shares of the medical equipment provider's stock worth $1,016,000 after buying an additional 4,779 shares during the period. Canada Post Corp Registered Pension Plan acquired a new stake in shares of Hologic during the fourth quarter worth $234,000. Finally, Aware Super Pty Ltd as trustee of Aware Super acquired a new stake in shares of Hologic during the fourth quarter worth $734,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on HOLX shares. Stephens decreased their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Evercore ISI increased their price objective on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Mizuho set a $75.00 price objective on shares of Hologic in a research report on Thursday, July 31st. Argus upgraded Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research note on Monday. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Stock Performance

Shares of Hologic stock traded down $0.54 on Monday, reaching $67.27. 2,084,235 shares of the company traded hands, compared to its average volume of 2,806,134. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The company has a 50 day moving average of $65.60 and a 200 day moving average of $62.50. The firm has a market capitalization of $14.96 billion, a PE ratio of 27.91, a PEG ratio of 2.46 and a beta of 0.49. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the firm posted $1.06 earnings per share. The company's quarterly revenue was up 1.2% compared to the same quarter last year. Equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.